MedAvail (MDVLQ) 10-Q 4 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 04, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	MYOS RENS TECHNOLOGY INC.
Entity Central Index Key	0001402479
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-53298
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NJ
Entity Common Stock, Shares Outstanding		11,846,795

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 1,334	$ 64
Accounts receivable, net	33	5
Inventories, net	1,474	1,666
Prepaid expenses	187	23
Total current assets	3,028	1,758
Operating lease right of use asset	165	192
Deferred offering costs		95
Fixed assets, net	88	97
Intangible assets, net	791	896
Total assets	4,072	3,038
Current liabilities:
Accounts payable	108	277
Accrued expenses and other current liabilities	3	230
Operating lease liabilities - current portion	37	46
Related party promissory note payable and accrued interest	654	1,159
Total current liabilities	802	1,712
Long-term liabilities:
Note Payable PPP loan	310
Operating lease liabilities - net of current portion	132	146
Total liabilities	1,244	1,858
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 500,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 15,000,000 shares authorized; 11,846,795 and 9,176,908 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	12	9
Additional paid-in capital	43,778	40,496
Accumulated deficit	(40,962)	(39,325)
Total stockholders' equity	2,828	1,180
Total liabilities and stockholders' equity	$ 4,072	$ 3,038

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	15,000,000	15,000,000
Common stock, shares issued	11,846,795	9,176,908
Common stock, shares outstanding	11,846,795	9,176,908

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net revenues	$ 329	$ 154	$ 619	$ 303
Cost of revenues	172	81	330	142
Gross profit	157	73	289	161
Operating expenses:
Selling, marketing and research	227	337	429	612
Personnel and benefits	365	470	833	890
General and administrative	329	432	644	788
Total operating expenses	921	1,239	1,906	2,290
Operating loss	(764)	(1,166)	(1,617)	(2,129)
Other expense, net	(7)	(9)	(20)	(21)
Net loss	$ (771)	$ (1,175)	$ (1,637)	$ (2,150)
Net loss per share attributable to common shareholders:
Basic and diluted	$ (0.07)	$ (0.13)	$ (0.15)	$ (0.23)
Weighted average number of common shares outstanding:
Basic and diluted	11,404,497	9,170,658	10,562,389	9,170,658

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows From Operating Activities:
Net loss	$ (1,637)	$ (2,150)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	9	13
Amortization	105	165
Stock-based compensation	227	71
Non-cash lease expense	27
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	(28)	62
Decrease in other current asset		1,124
Decrease (increase) in inventories	192	(1)
Increase in prepaid expenses and other assets	(164)	(87)
Decrease in operating lease liabilities	(23)
Increase in accrued interest expense	20	20
Decrease in accounts payable and accrued expenses	(396)	(352)
Net cash used in operating activities	(1,668)	(1,135)
Cash Flows From Financing Activities:
Proceeds from registered direct offering of common stock	1,298	428
Proceeds from related party promissory note	300
Proceeds from note payable PPP loan	310
Proceeds from issuance of common stock in private placement	1,030	1,850
Net cash provided by financing activities	2,938	2,278
Net increase in cash	1,270	1,143
Cash at beginning of period	64	15
Cash at end of period	1,334	1,158
Supplemental schedule of non-cash investing and financing activities:
Conversion of related party promissory note payable into shares of common stock	825	250
Reclassification of deferred offering costs to additional paid in capital	$ 95	$ 16

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes In Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated deficit	Total
Beginning balance at Dec. 31, 2018	$ 8	$ 37,880	$ (35,067)	$ 2,821
Beginning balance, shares at Dec. 31, 2018	7,481,723
Proceeds from sale of common stock, net		211		211
Proceeds from sale of common stock, net, shares	111,129
Proceeds from private placement of common stock	$ 1	1,849		1,850
Proceeds from private placement of common stock, shares	1,267,123
Issuance of common stock upon exchange of related party promissory note payable		250		250
Issuance of common stock upon exchange of related party promissory note payable, shares	171,233
Stock-based compensation expense		71		71
Stock-based compensation expense, shares
Issuance of restricted common stock		201		201
Issuance of restricted common stock, shares	139,450
Net loss			(2,150)	(2,150)
Ending balance at Jun. 30, 2019	$ 9	40,462	(37,217)	3,254
Ending balance, shares at Jun. 30, 2019	9,170,658
Beginning balance at Mar. 31, 2019	$ 9	40,434	(36,042)	4,401
Beginning balance, shares at Mar. 31, 2019	9,170,658
Stock-based compensation expense		28		28
Stock-based compensation expense, shares
Net loss			(1,175)	(1,175)
Ending balance at Jun. 30, 2019	$ 9	40,462	(37,217)	3,254
Ending balance, shares at Jun. 30, 2019	9,170,658
Beginning balance at Dec. 31, 2019	$ 9	40,496	(39,325)	1,180
Beginning balance, shares at Dec. 31, 2019	9,176,908
Proceeds from sale of common stock, net	$ 1	1,202		1,203
Proceeds from sale of common stock, net, shares	964,102
Proceeds from private placement of common stock	$ 1	1,029		1,030
Proceeds from private placement of common stock, shares	851,240
Issuance of common stock upon exchange of related party promissory note payable	$ 1	824		825
Issuance of common stock upon exchange of related party promissory note payable, shares	681,818
Stock-based compensation expense		18		18
Stock-based compensation expense, shares
Issuance of restricted common stock		209		209
Issuance of restricted common stock, shares	172,727
Net loss			(1,637)	(1,637)
Ending balance at Jun. 30, 2020	$ 12	43,778	(40,962)	2,828
Ending balance, shares at Jun. 30, 2020	11,846,795
Beginning balance at Mar. 31, 2020	$ 11	42,794	(40,191)	2,614
Beginning balance, shares at Mar. 31, 2020	11,030,100
Proceeds from sale of common stock, net	$ 1	974		975
Proceeds from sale of common stock, net, shares	816,695
Stock-based compensation expense		10		10
Stock-based compensation expense, shares
Net loss			(771)	(771)
Ending balance at Jun. 30, 2020	$ 12	$ 43,778	$ (40,962)	$ 2,828
Ending balance, shares at Jun. 30, 2020	11,846,795

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Liquidity	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY Nature of Operations MYOS RENS Technology Inc. (the "Company" or "MYOS") is focused on the discovery, development and commercialization of advanced nutrition products that improve muscle health and performance. The Company was incorporated under the laws of the State of Nevada on April 11, 2007. On March 17, 2016, the Company merged with its wholly-owned subsidiary and changed its name from MYOS Corporation to MYOS RENS Technology Inc. As used in these condensed consolidated financial statements, the terms "the Company", "MYOS", "our", or "we", refers to MYOS RENS Technology Inc. and its subsidiary, unless the context indicates otherwise. On February 25, 2011, the Company entered into an agreement to acquire the intellectual property for Fortetropin ® Our commercial focus is to leverage our clinical data to develop multiple products to target the large, but currently underserved, markets focused on muscle health. The sales channels through which we sell our products are evolving. The first product we introduced was MYO-T12, a proprietary formula containing Fortetropin ® In May 2016, we launched Physician Muscle Health Formula ® ® ® ® In March 2018, we launched Yolked®, a Fortetropin®-powered product which is NSF Certified for Sports, and developed and marketed to collegiate and professional athletes who want to increase their muscle size and performance with an all-natural advanced nutrition product. The Company recorded $104 and $121 of net revenues for the six months ended June 30, 2020 and June 30, 2019, respectively, for our Yolked® product line. In June 2018, we launched our Fortetropin ® In November 2019, we launched our white label business, working with manufacturers to create new brands and products using Fortetropin ® We continue to pursue additional distribution and branded sales opportunities. There can be no assurance that we will be able to secure distribution arrangements on terms acceptable to us, or that we will be able to generate significant sales of our current and future branded products. We expect to continue developing our own core branded products in markets such as functional foods, sports and fitness nutrition and to pursue international sales opportunities. We remain committed to continuing our focus on various clinical trials in support of enhancing our commercial strategy as well as enhancing our intellectual property assets, to develop product improvements and new products, and to reduce the cost of our products by finding more efficient manufacturing processes and contract manufacturers. Merger with MedAvail, Inc. Merger Agreement On June 30, 2020, MYOS and MedAvail, Inc., a privately-held Delaware corporation ("MedAvail"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), by and among MYOS, MedAvail, and Matrix Merger Sub, Inc., a newly-created wholly-owned subsidiary of MYOS ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into MedAvail, with MedAvail being the surviving corporation and a wholly-owned subsidiary of MYOS (the "Merger"). The Boards of Directors of MYOS and MedAvail have both approved the Merger and have recommended approval of the Merger by their respective shareholders. MedAvail is a private, in-clinic telemedicine-enabled pharmacy organization based in Ontario, Canada that has developed and commercialized a proprietary robotic dispensing platform and home delivery operation focused on the Medicare Advantage market in the United States. At the effective time of the Merger (the "Effective Time"): (a) each share of MedAvail's common stock and each share of MedAvail's preferred stock outstanding i mmediately prior to the Effective Time, excluding any dissenting shares, will be automatically converted solely into the right to receive a number of shares of MYOS common stock ("MYOS Common Stock") calculated according to the exchange ratio described below Immediately following the Merger, the name of the post-merger combined company (the "Post-Merger Combined Company") is expected to be changed from "MYOS RENS Technology Inc." to "MedAvail Holdings, Inc." The Merger Agreement provides that the Board of Directors of the Post-Merger Combined Company will consist of members who are currently directors of MedAvail. The executive officers of the Post-Merger Combined Company will be designated by MedAvail, with MedAvail's Chief Executive Officer, Ed Kilroy, expected to be the Post-Merger Combined Company's Chief Executive Officer and MedAvail's Chief Financial Officer, Ryan Ferguson, expected to be the Post-Merger Combined Company's Chief Financial Officer. The Merger Agreement contains certain customary termination rights, including, among others, (a) the right of either MYOS or MedAvail to terminate the Merger Agreement if the other party's stockholders fail to adopt and approve the Merger Agreement, (b) the right of either party to terminate the Merger Agreement if the other party's board of directors changes or withdraws its recommendation in favor of the transactions, (c) the right of either party to terminate the Merger Agreement if the Merger has not occurred by the six month anniversary of the date of the Merger Agreement, (d) the right of either party to terminate the Merger Agreement due to a material breach by the other party of any of its representations, warranties or covenants which would result in the closing conditions not being satisfied, subject to certain conditions, and (e) the right of either party to terminate the Merger Agreement if a court of competent jurisdiction or other governmental body issues a final and non-appealable order, decree or ruling, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Merger and related transactions. Upon the termination of the Merger Agreement by MYOS or MedAvail, a termination fee of (i) $500,000 may be payable by MYOS to MedAvail, or (ii) $750,000 may be payable by MedAvail to MYOS. Assignment and Assumption Agreement and Subscription and Stock Purchase Agreement The Merger Agreement provides that, prior to the consummation of the Merger, MYOS will transfer and assign all of its assets and liabilities into MYOS Corp., a newly-created, wholly-owned subsidiary of MYOS, pursuant to an Assignment and Assumption Agreement (the "Assignment and Assumption Agreement") and a related Subscription and Stock Purchase Agreement (the "Subscription and Stock Purchase Agreement"). The shares of MYOS Corp., immediately after the closing of the Merger, will be spun-out from the Post-Merger Combined Company through a dividend of the stock of MYOS Corp. to the pre-Merger MYOS shareholders, resulting in MYOS Corp., a private company, continuing the current business operations of MYOS. MedAvail will pay MYOS Corp. $2 million in cash upon the closing of the Merger and issue a promissory note for an additional $3 million, payable in installments within one year of the closing of the Merger. Amendment to Rights Agreement On June 30, 2020 MYOS entered into the Second Amendment to Rights Agreement (the "Amendment") with Transhare, as rights agent, which amends the Rights Agreement, dated as of February 14, 2017, previously entered into between MYOS and Island Stock Transfer as rights agent, as amended on February 14, 2020, with Transhare as the successor rights agent (the "Rights Agreement"). The Amendment amends the Rights Agreement to provide, among other things, that (i) neither the approval, execution, delivery or performance or, if approved by the board of directors of MYOS, amendment, modification or waiver of the Merger Agreement or the Voting Agreement or the consummation of the Merger or any other transaction contemplated by the Merger Agreement or the Voting Agreement, nor the public announcement of any of the foregoing will (a) cause any person to (1) become an Acquiring Person (as defined in the Rights Agreement) or be deemed to have become an Acquiring Person or (2) be deemed to have acquired Beneficial Ownership (as defined in the Rights Agreement) of any securities of MYOS or (b) result in the occurrence or deemed occurrence of a Distribution Date (as defined in the Rights Agreement), consolidation or merger or other event or occurrence resulting in a triggering of rights of holders of Rights (as defined in the Rights Agreement), or of obligations of MYOS under the Rights Agreement, and (ii) the Rights will expire in their entirety, and the Rights Agreement will terminate upon the earliest of (a) immediately prior to the Effective Time, (b) the Close of Business (as defined in the Rights Agreement) on February 21, 2021, (c) the time at which all Rights are redeemed, (d) the time at which all Rights are exchanged and (e) the closing of any merger or other acquisition involving MYOS at which time the Rights are terminated. Basis of Presentation The accompanying condensed consolidated balance sheet as of December 31, 2019 has been derived from our audited consolidated financial statements, and the unaudited interim condensed consolidated financial statements as of June 30, 2020 have been prepared in accordance with accounting principles generally accepted in the U.S. ("U.S. GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 24, 2020. The unaudited interim condensed consolidated financial statements presented herein reflect all normal adjustments that are, in the opinion of management, necessary for a fair presentation of the statement of the financial position, results of operations and cash flows for the periods presented. The results of any interim period are not necessarily indicative of the results for the full year. Going Concern and Liquidity The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, which contemplates the continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustment that might become necessary should the Company be unable to continue as a going concern. The Company has suffered recurring losses from operations and incurred a net loss of $1,637 for the six months ended June 30, 2020. The accumulated deficit as of June 30, 2020 was $40,962. The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its operating expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. These conditions indicate that there is substantial doubt about the Company's ability to continue as a going concern within one year after the condensed consolidated financial statement issuance date. As of June 30, 2020, the Company had cash of $1,334 and working capital of $2,226 (current assets of $3,028 less current liabilities of $802). For the six months ended June 30, 2020 and 2019, our net loss was $1,637 and $2,150, respectively. For the six months ended June 30, 2020 and 2019, net cash used in operating activities was $1,668 and $1,135, respectively. As of the filing date of this quarterly report on Form 10-Q (the "Report"), management believes that there may not be sufficient capital resources from operations and existing financing arrangements in order to meet operating expenses and working capital requirements for the next twelve months. Accordingly, we are evaluating various alternatives, including reducing operating expenses, securing additional financing through debt or equity securities to fund future business activities and other strategic alternatives. The Company entered into the Merger Agreement on June 30, 2020 and expects the Merger to close before the end of the year. There can be no assurance that the Company will be able to generate the level of operating revenues in its business plan, or if additional sources of financing will be available on acceptable terms, if at all. If no additional sources of financing are available, our future operating prospects may be adversely affected. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Since the date of the Annual Report on Form 10-K for the year ended December 31, 2019, there have been no material changes to the Company's significant accounting policies, except as disclosed in this note. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At June 30, 2020 and December 31, 2019, the Company had no cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. As part of our ongoing liquidity assessments management evaluates our cash and cash equivalents. The amount of funds held in these accounts can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities so the Company may at times have exposure to cash in excess of FDIC insured limits. At June 30, 2020, total cash in the Company's bank accounts was $1,334, which exceeded the FDIC coverage limit of $250. There were no accounts that exceeded the FDIC limit at December 31, 2019. Concentrations of Credit Risk, Customers and Suppliers Management regularly reviews accounts receivable, and if necessary, establishes an allowance for doubtful accounts that reflects management's best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Accounts receivable is non-interest bearing. Credit is issued to customers without collateral. If an account becomes delinquent, management will review if a write off is appropriate. Expense recognized as a result of an allowance for doubtful accounts is classified under general and administrative expenses in the condensed consolidated statements of operations. For the three and six months ended June 30, 2020 and 2019, the Company did not have any revenue, accounts receivable or supplier concentrations. Deferred Offering Costs The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering not be completed, deferred offering costs are charged to operations in accordance with SEC guidance. As of June 30, 2020 and December 31, 2019, deferred offering costs of $0 and $95, respectively, were included as a noncurrent asset on the accompanying condensed consolidated balance sheets related to a July 2018 sales agreement. Intangible Assets The Company's intangible assets consist primarily of intellectual property pertaining to Fortetropin ® Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor's patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Our policy is to evaluate intangible assets subject to amortization for possible impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using a discounted future cash flow method. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. There were no impairment charges for the three and six months ended June 30, 2020 and 2019. Intangible assets at June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, 2020 2019 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization – intellectual property (1,310 ) (1,205 ) Less: accumulated amortization - website (380 ) (380 ) Total intangible assets, net $ 791 $ 896 Amortization expense related to intangible assets for the six months ended June 30, 2020 and 2019 was $105 and $165, respectively, and $53 and $103 for the three months ended June 30, 2020 and 2019, respectively. Net Revenues Revenue Recognition Net revenues include products and shipping and handling charges, net of estimates for incentives and other sales allowances or discounts. Our product sales generally do not provide for rights of return. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at the point in time the customer obtains control of the products. We consider charges associated with shipping and handling activities as costs to fulfill our performance obligations. Using probability assessments, we estimate sales incentives expected to be paid over the term of the contract. The majority of our contracts have a single performance obligation and are short term in nature. Sales taxes that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net revenues. Disaggregation of Net Revenues Our net revenues by product type are presented below for the three months ended June 30, 2020 and 2019. Three months ended Product Type June 30, June 30, Myos Canine Muscle Formula® (1) $ 261 $ 89 Yolked® (2) 53 53 Longevity (includes Qurr® (3) and Physician Muscle Health Formula (4) brands) 4 12 White Label (5) 11 - Total Net Revenues $ 329 $ 154 Our net revenues by product type are presented below for the six months ended June 30, 2020 and 2019. Six months ended Product Type June 30, June 30, Myos Canine Muscle Formula® (1) $ 477 $ 150 Yolked® (2) 104 121 Longevity (includes Qurr® (3) and Physician Muscle Health Formula (4) brands) 10 32 White Label (5) 28 - Total Net Revenues $ 619 $ 303 (1) Launched in June 2018 (2) Launched in March 2018 (3) Launched in March 2017 (4) Launched in May 2016; relaunched in December 2019 (5) Launched in December 2019 Contract Assets and Liabilities The Company did not have any contract assets and contract liabilities from contracts with customers as of June 30, 2020 or December 31, 2019. Contract liabilities represent payments received from customers for which the Company had not yet satisfied its performance obligation under the contract. For the three and six months ended June 30, 2020 and 2019 there was no revenue recognized from performance obligations satisfied (or partially satisfied) in previous periods. Advertising, Marketing and Promotions The Company charges the costs of advertising to sales and marketing expenses as incurred. Advertising and marketing costs were $248 and $467 for the six months ended June 30, 2020 and 2019, respectively, and $70 and $131 for the three months ended June 30, 2020 and 2019, respectively. Advertising costs consisted primarily of marketing costs for our Yolked® and Myos Canine Muscle Formula® products. Shipping and Handling Costs The Company records costs for the shipping and handling of products to its customers in cost of revenues. These expenses were $16 and $16 for the six months ended June 30, 2020 and 2019, respectively and $7 and $10 for the three months ended June 30, 2020 and 2019, respectively. Research and Development Research and development expenses consist primarily of the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed. Research and development expenses were $27 and $89 for the six months ended June 30, 2020 and 2019, respectively and $5 and $80 for the three months ended June 30, 2020 and 2019, respectively. Basic and Diluted Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the "treasury stock" method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three and six months ended June 30, 2020 and 2019, the Company incurred a net loss. Accordingly, the Company's common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at June 30, 2020 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,034,740, which includes warrants to purchase an aggregate of 375,000 shares of common stock and options to purchase an aggregate of 659,740 shares of common stock and rights under the Rights Agreement. The aggregate number of potentially dilutive common stock equivalents outstanding at June 30, 2019 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,216,096 which includes warrants to purchase an aggregate of 663,356 shares of common stock and options to purchase an aggregate of 555,740 shares of common stock. Income Taxes On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act"). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. Under Accounting Standards Codification Topic 740 ("ASC 740"), Income Taxes

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENTLY ISSUED ACCOUNTING STANDARDS	NOTE 3 – RECENTLY ISSUED ACCOUNTING STANDARDS In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
INVENTORIES, NET	NOTE 4 – INVENTORIES, NET Inventories, net at June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, Raw materials $ 1,117 $ 1,264 Work in process 1 15 Finished goods 419 450 1,537 1,729 Less: inventory reserves (63 ) (63 ) Inventories, net $ 1,474 $ 1,666

Fixed Assets,Net

Fixed Assets,Net	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
FIXED ASSETS, NET	NOTE 5 – FIXED ASSETS, NET Fixed assets, net at June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, Furniture, fixtures and equipment $ 116 $ 116 Computers and software 68 68 Leasehold improvements 239 239 Other 7 7 Total fixed assets 430 430 Less: accumulated depreciation and amortization (342 ) (333 ) Net book value of fixed assets $ 88 $ 97 Depreciation expense was $9 and $13 for the six months ended June 30, 2020 and 2019, respectively, and $4 and $6 for the three months ended June 30, 2020 and 2019, respectively.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2020
Prepaid Expenses [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 6 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of various payments that the Company has made in advance for goods or services to be received in the future. Prepaid expenses and other current assets at June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, Prepaid consulting fees $ 57 $ 9 Prepaid legal fees 50 - Prepaid Nasdaq fees 22 - Prepaid marketing expenses 40 6 Prepaid other expenses 18 8 Total prepaid expenses and other current assets $ 187 $ 23

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 7 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of estimated future payments that relate to the current and prior accounting periods. Management reviews these estimates regularly to determine their reasonableness. Accrued expenses and other current liabilities at June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, Board compensation $ - $ 209 Other 3 21 Total accrued expenses and other current liabilities $ 3 $ 230

Related Party Promissory Note P

Related Party Promissory Note Payable	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
RELATED PARTY PROMISSORY NOTE PAYABLE	NOTE 8 – RELATED PARTY PROMISSORY NOTE PAYABLE On August 30, 2018, the Company issued an unsecured promissory note (the "Note") in the principal amount of $750 in favor of Joseph Mannello, the Company's chief executive officer (the "Lender"). The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the original Note were payable on March 31, 2020. On March 31, 2020, the Company modified its Note to extend the maturity to March 31, 2021. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owed under the Note, without penalty. In January 2020, the Lender advanced an additional $300 to the Company for general working capital purposes. On March 2, 2020, the Company entered into securities purchase agreements for a private placement with a group of accredited investors, including four members of the Company's board of directors. In connection with the closing of the private placement on March 5, 2020, the Company issued 851,240 shares of common stock for aggregate cash proceeds of $1,030 and $825 of the principal amount of the Note was exchanged for 681,818 shares of common stock. As of June 30, 2020, the total amounts outstanding under the Note was $580 of principal and $74 of accrued interest.

Note Payable - Paycheck Protect

Note Payable - Paycheck Protection Program	6 Months Ended
	Jun. 30, 2020
Note Payable Paycheck Protection Program [Abstract]
NOTE PAYABLE - PAYCHECK PROTECTION PROGRAM	Note 9 – NOTE PAYABLE – PAYCHECK PROTECTION PROGRAM On April 22, 2020, the Company received loan proceeds in the amount of $310 under the Paycheck Protection Program ("PPP"). The PPP, established as part of the CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1% per annum, with a deferral of payments for the first six months. The Company intends to use the proceeds for purposes consistent with the PPP. While the Company currently believes that its use of the loan proceeds will meet the conditions for forgiveness of the loan in whole, there can be no assurance that it will not take actions that could cause the Company to be ineligible for forgiveness of the loan, in whole or in part. As of June 30, 2020, no amount of the PPP loan had been forgiven.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
STOCKHOLDERS' EQUITY	Note 10 – Stockholders' Equity Authorized Capital As of June 30, 2020, the Company was authorized to issue 15,000,000 shares of common stock, $0.001 par value, and 500,000 shares of preferred stock, $0.001 par value. The holders of the Company's common stock are entitled to one vote per share. Preferred Stock Purchase Rights Effective February 14, 2017, the board of directors declared a dividend of one right ("Right") for each of the Company's issued and outstanding shares of common stock. The Rights were granted to the stockholders of record at the close of business on February 24, 2017. Each Right entitles the registered holder, upon the occurrence of certain events specified in the Rights Agreement, to purchase from the Company one one-thousandth of a share of the Company's Series A Preferred Stock at a price of $7.00, subject to certain adjustments. The Rights are not exercisable until the occurrence of certain events, including a person acquiring or obtaining the right to acquire beneficial ownership of 10% or more of the Company's outstanding common stock. The Rights are evidenced by certificates for the common stock and automatically transfer with the common stock unless they become exercisable. If the Rights become exercisable, separate certificates evidencing the Rights will be distributed to each holder of common stock. Holders of the preferred stock will be entitled to certain dividend, liquidation and voting rights. The Rights are redeemable by the Company at a fixed price as determined by the board of directors, after certain defined events. On February 14, 2020, the Company amended the Rights Agreement to, among other things extend the expiration date to February 14, 2021. In connection with the Merger Agreement, the Company amended the Rights Agreement on June 30, 2020 (see Note 1.) As of June 30, 2020, the Rights have no dilutive effect on the earnings per common share calculation and no shares of preferred stock have been issued. At the time of issuance, the Company determined that these Rights have a de minimis fair value. Issuance of Common Stock The Company has periodically issued common stock in connection with certain private and public offerings. For the six months ended June 30, 2020, the Company received aggregate net proceeds of $2,233 from these offerings: Net Date Shares Proceeds March 5, 2020 851,240 (1) $ 1,030 January 1, 2020 through June 30, 2020 at-the-market offerings 964,102 (2) 1,203 (1) Shares issued pursuant to a private placement with accredited investors for $1.21 per share. (2) Shares of common stock sold at various prices in at-the-market offerings from $1.18 to $1.55 per share. See Note 8 for a description of the issuance of common stock on March 5, 2020 in connection with the exchange of a portion of the related party promissory notes payable. At-the-Market Offering On January 23, 2020, the Company sold 7,322 shares of common stock for $1.50 per share for gross proceeds of $11 in an at-the-market offering. On February 3, 2020, the Company sold 140,085 shares of common stock for $1.55 per share for gross proceeds of $217 in an at-the-market offering. On May 12, 2020, the Company sold 81,695 shares of common stock for $1.18 per share for gross proceeds of $97 in an at-the-market offering. On May 26, 2020, the Company sold 735,000 shares of common stock for $1.38 per share for gross proceeds of $976 in an at-the-market offering. As of the filing date of this Report, a total of 1,075,231 shares were sold under this program for aggregate gross proceeds of $1,512 since the sales agreement began in July 2018.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 11 – STOCK-BASED COMPENSATION Equity Incentive Plan The Company increased the number of shares available for issuance under its 2012 Equity Incentive Plan (as amended, the "Plan") from 850,000 to 1,200,000 in December 2019, which was approved by the Company's shareholders in December 2019. The plan provides for the issuance of up to 1,200,000 shares. The Plan provides for grants of stock options, stock appreciation rights, restricted stock, other stock-based awards and other cash-based awards. As of June 30, 2020, the remaining shares of common stock available for future issuances of awards was increased due to forfeitures to 560,260. Stock options generally vest and become exercisable with respect to 100% of the common stock subject to such stock option on the third (3rd) anniversary of the date of grant. Any unvested portion of a stock option shall expire upon termination of employment or service of the participant granted the stock option, and the vested portion shall remain exercisable in accordance with the provisions of the Plan. Stock-Based Compensation Stock-based compensation consists of expenses related to the issuance of stock options and restricted stock. Stock-based compensation expenses were $9 and $28 for the three months ended June 30, 2020 and 2019, respectively, and $18 and $71 for the six months ended June 30, 2020 and 2019, respectively. On March 31, 2020, the Company issued 172,727 shares of its common stock with a fair value of $209 to members of its board of directors in connection with 2019 services. These restricted shares vested immediately upon issuance.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 12 – Commitments and Contingencies Defined Contribution Plan The Company established a 401(k) Plan (the "401(k) Plan") for eligible employees of the Company effective April 1, 2014. Generally, all employees of the Company who are at least twenty-one years of age and who have completed three months of service are eligible to participate in the 401(k) Plan. The 401(k) Plan is a defined contribution plan that provides that participants may make salary deferral contributions, of up to the statutory maximum allowed by law (subject to catch-up contributions) in the form of voluntary payroll deductions. As of April 1, 2020 the Company decided to not match 401(k) contributions until the Company becomes profitable. The Company's aggregate matching contributions were $11 and $18 for the six months ended June 30, 2020 and 2019, respectively, and $0 and $15 for the three months ended June 30, 2020 and 2019, respectively.

Operating Leases

Operating Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
OPERATING LEASES	Note 13 – OPERATING LEASES The Company has operating leases for its executive office (approximately 5,225 square feet of space) and office equipment. The remaining terms on these leases range from 3 to 4 years. The Company does not have any financing leases. The components of lease expense of $33 and $38 for the six months ended June 30, 2020 and June 30, 2019, respectively, were recorded in the condensed consolidated statements of operations. The components of lease expense of $18 and $22 for the three months ended June 30, 2020 and June 30, 2019, respectively, were recorded in the condensed consolidated statements of operations. There were no material operating and financing leases that the Company had entered into that were yet to commence as of June 30, 2020. Components of the Company's right-of-use assets and liabilities calculations are as follows: Cash paid for rent included in the measurement of operating lease liabilities cash flows $ 32 Right-of-use asset obtained in exchange for new operating lease liability 236 Weighted-average remaining lease term - operating leases, in years 2.55 Weighted-average discount rate - operating leases 11.7 % Future minimum lease payments for operating leases in excess of one year are as follows: For the year ending December 31, Amount 2020 $ 38 2021 77 2022 79 2023 3 Total future minimum lease payments 197 Imputed interest (28 ) Total $ 169

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	Note 14 – Related Party Transactions See Notes 8 and 10 for additional information relating to the Note issued to the Company's chief executive officer as well as details associated with the issuance of common stock to certain related parties in connection with securities purchase agreements.

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2020
Legal Proceedings [Abstract]
LEGAL PROCEEDINGS	Note 15 – legal PROCEEDINGS On January 6, 2017, in connection with the financing contemplated by a securities purchase agreement with RENS Technology Inc. (the "Purchaser"), we commenced an action in the Supreme Court of New York, County of New York (the "Court"), against the Purchaser, RENS Agriculture, the parent company of the Purchaser, and Ren Ren, a principal in both entities and one of our directors, arising from the Purchaser's breach of the agreement under which the Purchaser agreed to invest an aggregate of $20.25 million in our company in exchange for an aggregate of 3,537,037 shares of our common stock and warrants to purchase an aggregate of 884,259 shares of common stock. On April 11, 2017, the Court noted that we had demonstrated a likelihood of success on the merits of the breach of contract claim. Thereafter, a hearing was scheduled on the application by the Purchaser to dismiss the complaint and various pre-trial discovery applications by both parties. In August 2017, before the hearing occurred, the Company amended its complaint repeating most of the initial claims but adding several additional claims against RENS Agriculture, Mr. Ren and two additional Chinese defendants, including a claim against RENS Agriculture for breaching the exclusive distribution agreement, as well as claims against all defendants for theft and misappropriation of our confidential proprietary information and trade secrets, breach of fiduciary duty and duty of loyalty, misappropriation of corporate opportunity, unfair competition and a number of other torts. On July 13, 2020, the Company entered into a settlement agreement (the "Settlement Agreement") with the Purchaser, Mr. Ren and Mr. Mannello to settle all claims in connection with all pending litigation matters between the parties (the "Claims"). Pursuant to the Settlement Agreement, the parties agreed to file the appropriate documentation in the Nevada and New York courts to dismiss the Claims within five days of the execution of the Settlement Agreement. In addition, the Purchaser and Mr. Ren agreed to: (i) vote all of their shares of common stock of the Company in favor of the transactions contemplated by the Merger Agreement and (ii) waive and forfeit any right to receive any ownership interest in the private company (which will include the assets and liabilities for the Company's existing muscle health business) to be spun-out from the Company in connection with the Merger. The Purchaser also agreed that, simultaneous with the closing of the Merger, it will deliver its warrant to purchase 375,000 shares of common stock to the Company for cancellation or, if the warrant cannot be located, execute documents necessary to ensure that the warrant is cancelled. The Settlement Agreement further provides that Mr. Ren will resign as the Company's Global Chairman and as a member of the Company's board of directors upon the execution of the Settlement Agreement. The Settlement Agreement also includes mutual releases by the parties against each other for any claims or actions (including the Claims) through the date of the Settlement Agreement.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENT	Note 16 – SUBSEQUENT EVENT On July 13, 2020, the Company entered into the Settlement Agreement to settle all claims in connection with all pending litigation matters between the parties. The litigation was dismissed on July 23, 2020. (See Note 15)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At June 30, 2020 and December 31, 2019, the Company had no cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. As part of our ongoing liquidity assessments management evaluates our cash and cash equivalents. The amount of funds held in these accounts can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities so the Company may at times have exposure to cash in excess of FDIC insured limits. At June 30, 2020, total cash in the Company's bank accounts was $1,334, which exceeded the FDIC coverage limit of $250. There were no accounts that exceeded the FDIC limit at December 31, 2019.
Concentrations of Credit Risk, Customers and Suppliers	Concentrations of Credit Risk, Customers and Suppliers Management regularly reviews accounts receivable, and if necessary, establishes an allowance for doubtful accounts that reflects management's best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Accounts receivable is non-interest bearing. Credit is issued to customers without collateral. If an account becomes delinquent, management will review if a write off is appropriate. Expense recognized as a result of an allowance for doubtful accounts is classified under general and administrative expenses in the condensed consolidated statements of operations. For the three and six months ended June 30, 2020 and 2019, the Company did not have any revenue, accounts receivable or supplier concentrations.
Deferred Offering Costs	Deferred Offering Costs The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering not be completed, deferred offering costs are charged to operations in accordance with SEC guidance. As of June 30, 2020 and December 31, 2019, deferred offering costs of $0 and $95, respectively, were included as a noncurrent asset on the accompanying condensed consolidated balance sheets related to a July 2018 sales agreement.
Intangible Assets	Intangible Assets The Company's intangible assets consist primarily of intellectual property pertaining to Fortetropin ® Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor's patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Our policy is to evaluate intangible assets subject to amortization for possible impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using a discounted future cash flow method. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. There were no impairment charges for the three and six months ended June 30, 2020 and 2019. Intangible assets at June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, 2020 2019 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization – intellectual property (1,310 ) (1,205 ) Less: accumulated amortization - website (380 ) (380 ) Total intangible assets, net $ 791 $ 896 Amortization expense related to intangible assets for the six months ended June 30, 2020 and 2019 was $105 and $165, respectively, and $53 and $103 for the three months ended June 30, 2020 and 2019, respectively.
Net Revenues	Net Revenues Revenue Recognition Net revenues include products and shipping and handling charges, net of estimates for incentives and other sales allowances or discounts. Our product sales generally do not provide for rights of return. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at the point in time the customer obtains control of the products. We consider charges associated with shipping and handling activities as costs to fulfill our performance obligations. Using probability assessments, we estimate sales incentives expected to be paid over the term of the contract. The majority of our contracts have a single performance obligation and are short term in nature. Sales taxes that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net revenues. Disaggregation of Net Revenues Our net revenues by product type are presented below for the three months ended June 30, 2020 and 2019. Three months ended Product Type June 30, June 30, Myos Canine Muscle Formula® (1) $ 261 $ 89 Yolked® (2) 53 53 Longevity (includes Qurr® (3) and Physician Muscle Health Formula (4) brands) 4 12 White Label (5) 11 - Total Net Revenues $ 329 $ 154 Our net revenues by product type are presented below for the six months ended June 30, 2020 and 2019. Six months ended Product Type June 30, June 30, Myos Canine Muscle Formula® (1) $ 477 $ 150 Yolked® (2) 104 121 Longevity (includes Qurr® (3) and Physician Muscle Health Formula (4) brands) 10 32 White Label (5) 28 - Total Net Revenues $ 619 $ 303 (1) Launched in June 2018 (2) Launched in March 2018 (3) Launched in March 2017 (4) Launched in May 2016; relaunched in December 2019 (5) Launched in December 2019 Contract Assets and Liabilities The Company did not have any contract assets and contract liabilities from contracts with customers as of June 30, 2020 or December 31, 2019. Contract liabilities represent payments received from customers for which the Company had not yet satisfied its performance obligation under the contract. For the three and six months ended June 30, 2020 and 2019 there was no revenue recognized from performance obligations satisfied (or partially satisfied) in previous periods.
Advertising, Marketing and Promotions	Advertising, Marketing and Promotions The Company charges the costs of advertising to sales and marketing expenses as incurred. Advertising and marketing costs were $248 and $467 for the six months ended June 30, 2020 and 2019, respectively, and $70 and $131 for the three months ended June 30, 2020 and 2019, respectively. Advertising costs consisted primarily of marketing costs for our Yolked® and Myos Canine Muscle Formula® products.
Shipping and Handling Costs	Shipping and Handling Costs The Company records costs for the shipping and handling of products to its customers in cost of revenues. These expenses were $16 and $16 for the six months ended June 30, 2020 and 2019, respectively and $7 and $10 for the three months ended June 30, 2020 and 2019, respectively.
Research and Development	Research and Development Research and development expenses consist primarily of the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed. Research and development expenses were $27 and $89 for the six months ended June 30, 2020 and 2019, respectively and $5 and $80 for the three months ended June 30, 2020 and 2019, respectively.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the "treasury stock" method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three and six months ended June 30, 2020 and 2019, the Company incurred a net loss. Accordingly, the Company's common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at June 30, 2020 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,034,740, which includes warrants to purchase an aggregate of 375,000 shares of common stock and options to purchase an aggregate of 659,740 shares of common stock and rights under the Rights Agreement. The aggregate number of potentially dilutive common stock equivalents outstanding at June 30, 2019 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,216,096 which includes warrants to purchase an aggregate of 663,356 shares of common stock and options to purchase an aggregate of 555,740 shares of common stock.
Income Taxes	Income Taxes On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act"). The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. Under Accounting Standards Codification Topic 740 ("ASC 740"), Income Taxes

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of intangible assets	June 30, December 31, 2020 2019 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization – intellectual property (1,310 ) (1,205 ) Less: accumulated amortization - website (380 ) (380 ) Total intangible assets, net $ 791 $ 896
Schedule of disaggregation of revenues	Six months ended Product Type June 30, June 30, Myos Canine Muscle Formula® (1) $ 477 $ 150 Yolked® (2) 104 121 Longevity (includes Qurr® (3) and Physician Muscle Health Formula (4) brands) 10 32 White Label (5) 28 - Total Net Revenues $ 619 $ 303 Three months ended Product Type June 30, June 30, Myos Canine Muscle Formula® (1) $ 261 $ 89 Yolked® (2) 53 53 Longevity (includes Qurr® (3) and Physician Muscle Health Formula (4) brands) 4 12 White Label (5) 11 - Total Net Revenues $ 329 $ 154 (1) Launched in June 2018 (2) Launched in March 2018 (3) Launched in March 2017 (4) Launched in May 2016; relaunched in December 2019 (5) Launched in December 2019

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule of inventories, net	June 30, December 31, Raw materials $ 1,117 $ 1,264 Work in process 1 15 Finished goods 419 450 1,537 1,729 Less: inventory reserves (63 ) (63 ) Inventories, net $ 1,474 $ 1,666

Fixed Assets,Net (Tables)

Fixed Assets,Net (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of fixed assets, net	June 30, December 31, Furniture, fixtures and equipment $ 116 $ 116 Computers and software 68 68 Leasehold improvements 239 239 Other 7 7 Total fixed assets 430 430 Less: accumulated depreciation and amortization (342 ) (333 ) Net book value of fixed assets $ 88 $ 97

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Prepaid Expenses [Abstract]
Schedule of prepaid expenses and other current assets	June 30, December 31, Prepaid consulting fees $ 57 $ 9 Prepaid legal fees 50 - Prepaid Nasdaq fees 22 - Prepaid marketing expenses 40 6 Prepaid other expenses 18 8 Total prepaid expenses and other current assets $ 187 $ 23

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	June 30, December 31, Board compensation $ - $ 209 Other 3 21 Total accrued expenses and other current liabilities $ 3 $ 230

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of periodically issued common stock with certain private and public offerings	Net Date Shares Proceeds March 5, 2020 851,240 (1) $ 1,030 January 1, 2020 through June 30, 2020 at-the-market offerings 964,102 (2) 1,203 (1) Shares issued pursuant to a private placement with accredited investors for $1.21 per share. (2) Shares of common stock sold at various prices in at-the-market offerings from $1.18 to $1.55 per share.

Operating Leases (Tables)

Operating Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of other information related to leases	Cash paid for rent included in the measurement of operating lease liabilities cash flows $ 32 Right-of-use asset obtained in exchange for new operating lease liability 236 Weighted-average remaining lease term - operating leases, in years 2.55 Weighted-average discount rate - operating leases 11.7 %
Schedule of future minimum lease payments for operating leases	For the year ending December 31, Amount 2020 $ 38 2021 77 2022 79 2023 3 Total future minimum lease payments 197 Imputed interest (28 ) Total $ 169

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Liquidity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Nature of Operations, Basis of Presentation and Liquidity (Textual)
Net loss	$ (771)	$ (1,175)	$ (1,637)	$ (2,150)
Net revenues			28
Accumulated deficit	(40,962)		(40,962)		$ (39,325)
Cash	1,334	$ 1,158	1,334	1,158	64	$ 15
Working capital	2,226		2,226
Current assets	3,028		3,028		1,758
Current liabilities	802		802		$ 1,712
Net cash used in/provided by operating activities			$ (1,668)	(1,135)
Ownership of shares, description			Under the exchange ratio formula in the Merger Agreement, as of immediately after the Merger, the former MedAvail security holders are expected to own approximately 96.5% of the aggregate number of fully-diluted shares of MYOS Common Stock outstanding following the consummation of the Merger (the "Post-Closing Shares"), and the stockholders of MYOS immediately prior to the Merger are expected to own approximately 3.5% of the Post-Closing Shares, subject to the adjustments set forth in the Merger Agreement.
Myos [Member]
Nature of Operations, Basis of Presentation and Liquidity (Textual)
Cash	2,000		$ 2,000
Termination fee payable			750,000
Promissory note	$ 3,000		3,000
MedAvail, Inc. [Member]
Nature of Operations, Basis of Presentation and Liquidity (Textual)
Termination fee payable			500,000
YOLKED [Member]
Nature of Operations, Basis of Presentation and Liquidity (Textual)
Net revenues			104	121
Myos Canine Muscle Formula [Member]
Nature of Operations, Basis of Presentation and Liquidity (Textual)
Net revenues			477	150
Physician Muscle Health Formula [Member]
Nature of Operations, Basis of Presentation and Liquidity (Textual)
Net revenues			$ 10	$ 32

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Intangibles with finite lives:
Total intangible assets, net	$ 791	$ 896
Intellectual property [Member]
Intangibles with finite lives:
Intangibles with finite lives	2,101	2,101
Less: accumulated amortization	(1,310)	(1,205)
Website - qurr.com [Member]
Intangibles with finite lives:
Intangibles with finite lives	380	380
Less: accumulated amortization	$ (380)	$ (380)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total Net Revenues		$ 329	$ 154	$ 619	$ 303
Myos Canine Muscle Formula® [Member]
Total Net Revenues	[1]	261	89	477	150
Yolked® [Member]
Total Net Revenues	[2]	53	53	104	121
Longevity includes Qurr® and Physician Muscle Health Formula brands [Member]
Total Net Revenues	[3],[4]	4	12	10	32
White Label [Member]
Total Net Revenues	[5]	$ 11		$ 28
[1]	Launched in June 2018
[2]	Launched in March 2018
[3]	Launched in March 2017
[4]	Launched in May 2016; relaunched in December 2019
[5]	Launched in December 2019

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2014	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2011
Summary of Significant Accounting Policies (Textual)
Advertising and promotional costs		$ 70	$ 131	$ 248	$ 467
Research and development cost		5	80	$ 27	$ 89
Potentially dilutive common stock equivalents outstanding				1,034,740	1,216,096
Deferred offering costs						$ 95
Cash in bank accounts		1,334	1,158	1,334	$ 1,158	$ 64	$ 15
FDIC coverage limit		250		250
Shipping and handling expenses		7	10	16	16
Amortization		$ 52	103	$ 105	165
Sale of product					72
Intangible assets, terms				Upon issuance of the patent, capitalized patent costs are reclassified to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years.
Intangible assets			$ 105		$ 105
Warrant [Member]
Summary of Significant Accounting Policies (Textual)
Potentially dilutive common stock equivalents outstanding				663,356	375,000
Options [Member]
Summary of Significant Accounting Policies (Textual)
Potentially dilutive common stock equivalents outstanding				659,740	555,740
Shipping and Handling [Member]
Summary of Significant Accounting Policies (Textual)
Sale of product				$ 9	$ 5
Patents [Member]
Summary of Significant Accounting Policies (Textual)
Intellectual property asset, fair value								$ 2,000
Intellectual Property [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets	10 years

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Summary of Inventory
Raw materials	$ 1,117	$ 1,264
Work in process	1	15
Finished goods	419	450
Inventories, gross	1,537	1,729
Less: inventory reserves	(63)	(63)
Inventories, net	$ 1,474	$ 1,666

Fixed Assets,Net (Details)

Fixed Assets,Net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total fixed assets	$ 430	$ 430
Less: accumulated depreciation and amortization	(342)	(333)
Net book value of fixed assets	88	97
Furniture, fixtures and equipment [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets	116	116
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets	68	68
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets	239	239
Other [Member]
Property, Plant and Equipment [Line Items]
Total fixed assets	$ 7	$ 7

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Fixed Assets (Textual)
Depreciation expense	$ 4	$ 6	$ 9	$ 13

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Prepaid Expenses [Abstract]
Prepaid consulting fees	$ 57	$ 9
Prepaid legal fees	50
Prepaid Nasdaq fees	22
Prepaid marketing expenses	40	6
Prepaid other expenses	18	8
Total prepaid expenses and other current assets	$ 187	$ 23

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Board compensation		$ 209
Other	3	21
Total accrued expenses and other current liabilities	$ 3	$ 230

Related Party Promissory Note_2

Related Party Promissory Note Payable (Details) - USD ($) $ in Thousands	Mar. 02, 2020	Jun. 30, 2020	Jan. 31, 2020	Aug. 30, 2018
Related Party Promissory Note and Accrued Interest (Textual)
Lender advanced additional of funds			$ 300
Note payable, description		The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the original Note were payable on March 31, 2020.
Accrues interest percentage		5.00%
Accrued interest expense		$ 74
Amounts outstanding principal		$ 580
Securities Purchase Agreement [Member]
Related Party Promissory Note and Accrued Interest (Textual)
Note payable, description	The Company entered into securities purchase agreements for a private placement with a group of accredited investors, including four members of the Company's board of directors. In connection with the closing of the private placement on March 5, 2020, the Company issued 851,240 shares of common stock for aggregate cash proceeds of $1,030 and $825 of the principal amount of the Note was exchanged for 681,818 shares of common stock.
Joseph Mannello [Member]
Related Party Promissory Note and Accrued Interest (Textual)
Unsecured promissory note principal amount				$ 750

Note Payable _ Paycheck Protect

Note Payable – Paycheck Protection Program (Details) - Paycheck Protection Program [Member] $ in Thousands	1 Months Ended
	Apr. 22, 2020USD ($)
Note Payable – Paycheck Protection Program (Textual)
Loan received	$ 310
Payment protection program, description	The PPP, established as part of the CARES Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business.
Payment protection program interest rate	1.00%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Common Stock [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)shares
March 5, 2020 [Member]
Class of Stock [Line Items]
Shares | shares	851,240	[1]
Net Proceeds | $	$ 1,030
January 1, 2020 through June 30, 2020 [Member]
Class of Stock [Line Items]
Shares | shares	964,102	[2]
Net Proceeds | $	$ 1,203
[1]	Shares issued pursuant to a private placement with accredited investors for $1.21 per share.
[2]	Shares of common stock sold at various prices in at-the-market offerings from $1.18 to $1.55 per share.

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	May 26, 2020	May 12, 2020	Feb. 03, 2020	Feb. 14, 2017	Jan. 23, 2020	Jul. 31, 2018	Jun. 30, 2020	Dec. 31, 2019
Stockholders' Equity (Textual)
Common stock, shares authorized							15,000,000	15,000,000
Common stock, par value							$ 0.001	$ 0.001
Preferred stock, shares authorized							500,000	500,000
Preferred stock, par value							$ 0.001	$ 0.001
Proceeds from issuance of private placement and public offering							$ 2,233
Sale of common stock, shares						1,075,231
Gross proceeds of common stock value						$ 1,512
Common Stock [Member]
Stockholders' Equity (Textual)
Sale of common stock, shares	735,000	81,695	140,085		7,322
Sale of purchase price per share	$ 1.38	$ 1.18	$ 1.55		$ 1.50
Gross proceeds of common stock value	$ 976	$ 97	$ 217		$ 11
Private Placement [Member]
Stockholders' Equity (Textual)
Sale of purchase price per share							$ 1.21
At The Market Offerings [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Sale of purchase price per share							1.55
At The Market Offerings [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Sale of purchase price per share							$ 1.18
Series A Preferred Stock [Member]
Stockholders' Equity (Textual)
Series A preferred stock purchase right, description				Each Right entitles the registered holder, upon the occurrence of certain events specified in the Rights Agreement, to purchase from the Company one one-thousandth of a share of the Company’s Series A Preferred Stock at a price of $7.00, subject to certain adjustments.

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses		$ 209
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance	1,200,000			1,200,000
Common stock reserved for issuance awards increased due to forfeitures	560,260			560,260
Stock options exercisable, description				Stock options generally vest and become exercisable with respect to 100% of the common stock subject to such stock option on the third (3rd) anniversary of the date of grant.
2012 Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance						850,000
2012 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance						1,200,000
Share-Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance		172,727
Stock-based compensation expenses	$ 9		$ 28	$ 18	$ 71

Commitments and Contingencies (

Commitments and Contingencies (Details)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies (Textual)
Defined contribution plan, description	All employees of the Company who are at least twenty-one years of age and who have completed three months of service are eligible to participate in the 401(k) Plan. The 401(k) Plan is a defined contribution plan that provides that participants may make salary deferral contributions, of up to the statutory maximum allowed by law (subject to catch-up contributions) in the form of voluntary payroll deductions. As of April 1, 2020 the Company decided to not match 401(k) contributions until the Company becomes profitable. The Company's aggregate matching contributions were $11 and $18 for the six months ended June 30, 2020 and 2019, respectively, and $0 and $15 for the three months ended June 30, 2020 and 2019, respectively.

Operating Leases (Details)

Operating Leases (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Leases [Abstract]
Cash paid for rent included in the measurement of operating lease liabilities cash flows	$ 32
Right-of-use asset obtained in exchange for new operating lease liability	$ 236
Weighted-average remaining lease term - operating leases, in years	2 years 6 months 18 days
Weighted-average discount rate - operating leases	11.70%

Operating Leases (Details 1)

Operating Leases (Details 1) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
2020	$ 38
2021	77
2022	79
2023	3
Total future minimum lease payments	197
Imputed interest	(28)
Total	$ 169

Operating Leases (Details Textu

Operating Leases (Details Textual) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)ft²	Jun. 30, 2019USD ($)
Lease expense | $	$ 18	$ 22	$ 33	$ 38
Leases Agreement [Member] | Office Equipment [Member]
Area | ft²	5,225		5,225
Minimum [Member]
Operating leases term	3 years		3 years
Maximum [Member]
Operating leases term	4 years		4 years

Legal Proceedings (Details)

Legal Proceedings (Details) - Rens Technology Inc [Member] - USD ($) $ in Thousands	Jan. 06, 2017	Jul. 13, 2020
Legal Proceedings (Textual)
Aggregate purchase of warrant	884,259
Aggregate purchase of investment	$ 20,250
Aggregate exchange for common stock	3,537,037
Subsequent Event [Member]
Legal Proceedings (Textual)
Number of common stock purchased by warrant		375,000